Table 4.
Univariate analysis of the CT features and DPC4 gene expression in 150 patients with T3 tumours
| Variable | DPC4-expression (n = 66) | DPC4-non-expression (n = 84) | p-value | |
|---|---|---|---|---|
| Tumour size (mm) | Longest axial diameter | 29.7 ± 11.8 | 28.9 ± 9.8 | 0.985 |
| Tumour location | Head | 41 (62.1%) | 61 (72.6%) | 0.217 |
| Body/tail | 25 (37.9%) | 23 (27.4%) | ||
| Tumour homogeneity | Homogeneous | 13 (19.7%) | 11 (13.1%) | 0.274 |
| Heterogeneous | 53 (80.3%) | 73 (86.9%) | ||
| Tumour marginsa | Well defined | 33 (54.1%) | 30 (37.0%) | 0.043 |
| Ill defined | 28 (45.9%) | 51 (63.0%) | ||
| IPMN background | Presence | 5 (7.6%) | 3 (3.6%) | 0.279 |
| Absence | 61 (92.4%) | 81 (96.4%) | ||
| Intratumoural calcification | Presence | 3 (4.5%) | 1 (1.2%) | 0.206 |
| Absence | 63 (95.5%) | 83 (98.8%) | ||
| Pancreatic duct dilatation | Presence | 49 (74.2%) | 66 (78.6%) | 0.534 |
| Absence | 17 (25.8%) | 18 (21.4%) | ||
| Upstream atrophy | Presence | 17 (25.8%) | 25 (29.8%) | 0.588 |
| Absence | 49 (74.2%) | 59 (70.2%) | ||
| Bile duct dilatation | Presence | 34 (51.5%) | 44 (52.4%) | 0.916 |
| Absence | 32 (48.5%) | 40 (47.6%) | ||
| Peripancreatic infiltration | Presence | 58 (87.9%) | 82 (97.6%) | 0.018 |
| Absence | 8 (12.1%) | 2 (2.4%) | ||
| Organ invasion | Presence | 14 (21.2%) | 9 (10.7%) | 0.077 |
| Absence | 52 (78.8%) | 75 (89.3%) | ||
| Artery invasion | Presence | 23 (34.8%) | 35 (41.7%) | 0.385 |
| Absence | 43 (65.2%) | 49 (58.3%) | ||
| Vein invasion | Presence | 23 (34.8%) | 32 (38.1%) | 0.682 |
| Absence | 43 (65.2%) | 52 (61.9%) | ||
| Lymph node enlargements | Presence | 36 (54.5%) | 39 (46.4%) | 0.324 |
| Absence | 30 (45.5%) | 45 (53.6%) | ||
| Arterial-phase densityb | Hypodensity | 62 (95.4%) | 70 (94.6%) | 0.832 |
| Isodensity | 3 (4.6%) | 4 (5.4%) | ||
| Hyperdensity | 0 (0.0%) | 0 (0.0%) | ||
| Portal-phase density | Hypodensity | 62 (93.9%) | 79 (94.0%) | 0.978 |
| Isodensity | 4 (6.1%) | 5 (6.0%) | ||
| Hyperdensity | 0 (0.0%) | 0 (0.0%) | ||
| Arterial enhancement ratio (%)b | 0.60 ± 0.16 | 0.56 ± 0.16 | 0.224 | |
| Portal enhancement ratio (%) | 0.65 ± 0.18 | 0.65 ± 0.17 | 0.979 | |
IPMN, intraductal papillary mucinous neoplasm.
a
Tumour margin was evaluated in 142 pancreatic ductal adenocarcinomas because 8 adenocarcinomas with an IPMN in the background parenchyma could not be evaluated.
b
Arterial-phase density was assessed in 139 pancreatic ductal adenocarcinomas due to the unavailability of arterial-phase images in 11 adenocarcinomas. The arterial enhancement ratio and arterial/portal enhancement ratio were calculated in 139 pancreatic ductal adenocarcinomas.